Core Viewpoint - Ultragenyx Pharmaceutical's experimental drug for a genetic bone disease failed to meet its primary endpoint in late-stage clinical trials [1] Company Summary - Ultragenyx Pharmaceutical announced the results of its late-stage studies regarding its experimental drug [1]